Related Experiment Video
Updated: Jun 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Repositioning renal denervation in resistant hypertension: evidence-based insights, stratified decision-making, and
Min Li1, Ding Yang1, Xu Cheng1
1Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
None:
Renal denervation (RDN) is a catheter-based interventional approach that targets renal sympathetic nerves to modulate sympathetic overactivity, a key pathophysiological driver of resistant hypertension and associated cardiovascular complications. In contrast to pharmacological approaches, the therapeutic effect of RDN does not rely on patient adherence. Originally indicated for severe resistant hypertension, RDN has since shown consistent antihypertensive efficacy across a broad range of hypertensive patients in recent sham-controlled studies. In this review, we discuss the pathophysiological foundation underlying RDN, consolidate the current clinical evidence supporting its therapeutic efficacy, describe the spectrum of available ablation technologies, and evaluate its expanding applications in conditions driven by sympathetic overactivity.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Hypertension V: Nursing Management
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
